Navigation Links
GeoVax Labs, Inc. Announces Second Quarter Financial Results
Date:8/12/2011

ATLANTA, Aug. 12, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based, biopharmaceutical firm (the "Company") developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced its financial results and provided an operational update for the six months ended June 30, 2011.

GeoVax reported a net loss of $211,344 ($0.01 per share) for the three months ended June 30, 2011, compared to $933,089 ($0.06 per share) for the same period in 2010. For the six months ended June 30, 2011, the Company's net loss was $817,626 ($0.05 per share) as compared to $1,623,878 ($0.10 per share) in 2010.  Net losses were partially offset by revenues related to the Company's grant from the NIH in support of the its HIV/AIDS vaccine development activities; such revenues were $1,753,033 and $2,646,035 for the three month and six month periods of 2011, respectively, as compared to $1,737,169 and $3,075,729 for the three month and six month periods of 2010, respectively.  As of June 30, 2011, the Company reported cash balances totaling $668,055, as compared to $1,079,087 at December 31, 2010.

GeoVax President and CEO Robert T. McNally, PhD, commented, "While the continued progress of our clinical development programs remains our priority, financing efforts have represented a major activity during the last quarter.  Our current cash balances, together with anticipated proceeds from our NIH grant, are sufficient to support our planned operations into 2012.  Although current market conditions present a challenging environment, we remain confident that we will achieve the funding necessary to advance our vaccine development programs."

Dr. McNally continued, "Our opening the Los Angeles, AIDS Research Alliance (ARA) site, has added to the number of individuals currently being stabilized on conventional oral medications in preparation for vaccination in our Phase 1 therapeutic trial.  A stabiliza
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
5. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
6. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
7. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
8. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
10. GeoVax Secures $10 Million Financing Commitment
11. GeoVax Reports Progress on Its AIDS Vaccine Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014   Royal Philips ... announced it has received 510(k) clearance from the ... precision planning application for Transcatheter Aortic-Valve Implantation (TAVI) ... provides interventionalists with pre-procedural, high-precision positioning to treat ... planning application is available as part of Philips ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Indiana blocked the sale of more ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Calif., Oct. 28 Watson Pharmaceuticals, Inc. (NYSE: ... announced today that its subsidiary Watson Laboratories, Inc. ... on outstanding patent litigation related to Watson,s Oxytrol® ... August 19, 2008, Barr submitted an Abbreviated New ...
... 27 Cambrex Corporation (NYSE: CBM ) announced that third quarter 2009 financial results will be ... conference call to discuss the third quarter 2009 financial results. , , ... 2009 Earnings Conference Call, When: ... 1-888-634-4003 for U.S., ...
Cached Medicine Technology:Watson and Barr Settle Lawsuit Over Oxytrol(R) 2
(Date:8/21/2014)... DURHAM, NC -- Researchers have pinpointed the environmental source ... in Southern California for decades. It literally grows on ... project of a 13-year-old girl, who spent the summer ... Angeles hardest hit by infections of the fungus named ... Cryptococcus , which encompasses a number of species ...
(Date:8/21/2014)... California (PRWEB) August 21, 2014 The ... initial plans for entertainment and programming for its inaugural ... On Sunday, October 12, 2014, from 11 a.m. to ... closed to all cars and the downtown will be ... activities, curated by Community Arts Resources (CARS), for all ...
(Date:8/21/2014)... (HealthDay News) -- Not only is eating better and exercising ... of health-care dollars a year, a new study finds. ... health sciences at Wake Forest Baptist Medical Center in Winston-Salem, ... 2 diabetes patients. Participants ranged in age ... an intensive "lifestyle change program" focused on diet and exercise, ...
(Date:8/21/2014)... seniors, dimming vision may be tied to poorer survival, new ... aged 65 to 84, who were assessed when they enrolled ... later. Vision loss over time was associated with an ... period, the researchers reported. Although the study couldn,t prove ... University in West Lafayette, Ind., offered up some theories on ...
(Date:8/21/2014)... The W. Montague Cobb/ NMA Health ... voice in the elimination of health disparities, honored ... 112th National Medical Association’s (NMA) Annual Convention and ... Ruffin, Ph.D, former Director of the National Institute ... career and innovations have had a significant impact ...
Breaking Medicine News(10 mins):Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2
... is associated with a statistically significant increase in cancer risk ... of the breast, liver, rectum, and upper aero-digestive tract combined, ... of the Journal of the National Cancer Institute. ... known about the impact of low to moderate alcohol consumption ...
... are sent to a cardiologist to go through a standard ... evidence of coronary artery disease which is the most common ... in men, and these women are sent home with little ... complaining of similar symptoms and are more likely to develop ...
... Postpartum depression is a seriousand often undiagnosedcondition affecting about ... the causes might include personal history of depression, stressful ... support. Left untreated, it can have lasting negative effects ... development. , In the first study of ...
... And that can pose a big public health threat, ... Following their release from Texas prisons, only 5 percent ... to treat their condition within the necessary 10 days, ... [antiretroviral therapy] at this time are at increased risk ...
... Experts agree that field needs more rigorous trials to aid ... of the guidelines for cardiac care issued by the American ... supported by the kind of gold-standard evidence that doctors respect ... come from heretics crying in the wilderness. One author of ...
... Telekenex, Inc ("Telekenex"), today announced it has ... MPLS network over the weekend from Straitshot Communications ... the challenge and worked straight through the weekend ... its network. One of these companies, Evergreen ...
Cached Medicine News:Health News:Million women study shows even moderate alcohol consumption associated with increased cancer risk 2Health News:Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain 2Health News:Diabetes a risk factor for postpartum depression 2Health News:Most HIV-Infected Prisoners Go Untreated After Release 2Health News:Weak Evidence Backs Most Heart Guidelines, Report Finds 2Health News:Weak Evidence Backs Most Heart Guidelines, Report Finds 3Health News:Evergreen Healthcare and Others Successfully Migrate to the Telekenex Network From Straitshot 2
Single-Piece PMMA Intraocular Lenses....
Single Piece PMMA Lens (Refractive and Bifocal). Anterior chamber Lens....
Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
STABIBAG Hydrophilic Acrylic Lens....
Medicine Products: